{"id":"W4220862006","doi":"10.3324/haematol.2021.279459","title":"Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Calgary","funders":"National Cancer Institute; Adaptive Biotechnologies; Regeneron Pharmaceuticals; Janssen Pharmaceuticals; Celgene; Pharmacyclics; Sanofi; Chugai Pharmaceutical; Daiichi-Sankyo; Pfizer; Amgen","keywords":"Daratumumab; Medicine; Internal medicine; Neutropenia; Gastroenterology; Population; Adverse effect; Multiple myeloma; Lenalidomide; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005415962,0.001154019,0.002406653,0.0003817935,0.0003793764,0.001411534,0.0006442809,0.0009291206,0.002998185],"category_scores_gemma":[0.002709416,0.0005210817,0.00289214,0.0003968246,0.0006648122,0.0005963831,0.0003967492,0.00277805,0.000572793],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008395151,"about_ca_system_score_gemma":0.001517673,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004472451,"about_ca_topic_score_gemma":0.001593465,"domain_scores_codex":[0.9984915,0.001046304,0.00004987476,0.0001195113,0.0001233174,0.0001694136],"domain_scores_gemma":[0.9982477,0.0005918427,0.0004376651,0.0001712034,0.0001486964,0.000402828],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8905142,0.01029985,0.007111968,0.0008476891,0.004382689,0.0001933905,0.0002449191,0.002298887,0.04154355,0.0004395814,0.002141213,0.03998201],"study_design_scores_gemma":[0.6997716,0.2531499,0.03162734,0.00006323132,0.002473539,0.00022769,0.00008417029,0.002266217,0.005264046,0.0004493151,0.004566642,0.00005629706],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891745,0.002271554,0.001817153,0.0005170977,0.0001475684,0.002826577,0.001593138,0.0001355431,0.00151689],"genre_scores_gemma":[0.9907584,0.0007490367,0.00188769,0.0004607821,0.0001320216,0.002557086,0.001693765,0.00004376701,0.001717449],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005415962,"threshold_uncertainty_score":0.02864265,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03769452657367144,"score_gpt":0.3114860319042406,"score_spread":0.2737915053305691,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}